| INTRODUC TI ON
Chromosomal microarray analysis (CMA) has been found to be useful to identify prenatal clinically relevant copy number variations (CNVs). 1 Compared with karyotype, CMA can achieve a better resolution for chromosomal imbalances and submicroscopic genomic alterations in the context of whole genome screening, both prenatal and postnatal. [2] [3] [4] Therefore, it will soon be considered standard to use CMA for the evaluation of pregnancies with anomalies. 1 This method should provide better decision guidance for the parents and physicians, but the complex ethics have to been weighed carefully. 5, 6 Indeed, variants of unknown significance (VOUS) pose a challenge for proper prenatal genetic counseling 7 because of their unknown penetrance and clinical impact. In addition, VOUS may be present in a substantial proportion of tested patients, for example, as high as in 15% in studies of hypertrophic cardiomyopathy, 8, 9 but this proportion may vary depending on the number and nature of the genes being tested. Most importantly, despite the fact that their biological impact is unknown, their psychological impact on the parents and their family is undeniable as VOUS lead to stress in the face of uncertainty and because of the decision of continuing pregnancy or not. 10 It has been shown that exploring uncertainty during the communication process is important for the patient and family experience in the presence of a VOUS. 11 Communication among the family members and the physicians is paramount. 10 Furthermore, a VOUS may be in fact pathogenic, but has been classified as VOUS simply because of insufficient data to determine its real pathogenic potential. Therefore, a better understanding of the VOUS is necessary in order to provide adequate prenatal genetic counseling.
Nevertheless, uncertainty will be an inherent part of genetic counseling for some time to come.
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Congenital heart defects (CHDs) represent the most frequent type of fetal anomalies in China, with a prevalence of eight per 1000 live births. 13 CHDs are often found on ultrasound during prenatal diagnosis, and etiology is unknown in most cases, 14 but recent findings highlighted molecular pathways in heart development.
Chromosomal aberrations and single-gene defects are considered to be the main potential etiology of CHDs. 15, 16 The exact genetic causes of CHDs remain largely unknown, but CHDs have been associated with chromosomal abnormalities, chromosome 22q11.2 deletion, 17 and rare CNVs. 1, 18 Studies showed that there are pathogenic
CNVs associated with the tetralogy of Fallot, thoracic aortic aneurysms, and congenital left-sided heart disease, among others. 18, 19 Nevertheless, studies are still necessary to improve the definition of the role of CMA in CHD diagnosis due to the gap between studies focusing on prenatal and postnatal phenotypes. In addition, because of the increasing availability of CMA and of its sensitivity to any genetic change, 20, 21 VOUS found by CMA represent a growing problem.
Therefore, the aim of this study was to use CMA to analyze 190 fetuses with CHDs and normal karyotype, to follow the pregnancy, to examine the CHD status of the born infants, and to evaluate the potential value of CMA for the prenatal diagnosis of CHD. This study could also allow the estimation of the pathogenic potential of some VOUS, therefore improving genetic counseling.
| MATERIAL S AND ME THODS

| Case selection
A total of 207 fetuses diagnosed with CHD by fetal ultrasound and that underwent CMA were retrospectively reviewed.
Invasive prenatal diagnosis was performed between January 2015 and December 2016 at the first affiliated hospital of Air Force Medical University (Shanxi Province, Northwest China).
All parents had received prenatal counseling from a clinical geneticist regarding the risks related to invasive prenatal diagnosis, the benefits and limitations of CMA, and the risks of VOUS and incidental findings. The inclusion criteria were as follows: (a) di- 
| Karyotype analysis
Amniotic fluid (30 mL) or fetal blood (1 mL) was sampled at 18-32 gestational weeks by amniocentesis or cordocentesis after obtaining informed consent from the parents. Standard cytogenetic protocols were applied to the samples. 22 The Giemsa-banding technique (450-550-band resolution) was used to analyze the cultured amniocytes or lymphocytes.
| DNA preparation
A QIAamp DNA Blood Mini Kit (Qiagen, Venlo, the Netherlands) was used to extract genomic DNA from amniotic fluid (10 mL) or umbilical cord blood (2 mL). The concentration and quality of genomic DNA were analyzed using a NanoDrop 2000 (Thermo Fisher Scientific, Waltham, MA, USA). were not considered for this study.
| CMA
| FISH study of chromosome 22q11.2
Chromosome 22q11.2 deletion was analyzed by FISH on interphase nuclei using a commercial probe, according to standard protocols. 24 
| RE SULTS
| Characteristics of the cases
During the study period, 207 pregnancies with CHD detected ultrasonographically underwent both karyotype and CMA analysis. A total of 17 chromosomal aberrations were identified by karyotype (Table 1) . Ultrasound features were highly variable among the fetuses, but were all determined as being abnormal.
| Detection rates of CNVs with normal karyotype by CMA
Chromosomal microarray analysis detected pCNVs in 13 (6.8%, 
13/190) fetuses (
| D ISCUSS I ON
The ethics involved in prenatal genetic counseling and diagnosis are complex. 5, 6 Indeed, VOUS pose a challenge for proper prenatal genetic counseling. 7 Therefore, a better understanding of the clinically significant genetic variants is necessary. Most fetal cases of CHD will be identified by conventional karyotyping, but this method is limited and most of the findings are aneuploidies and triploidies. The increasing use of CMA revealed a large number of CNVs in a number of disorders. 25 Recently, studies underlined the important role of CNVs in many developmental conditions such as CHD. 26 In the present study, all cases of pathogenic CNV either underwent termination of pregnancy (n = 12) or were stillborn (n = 1). Among the Born, normal five cases of likely pathogenic CNV, two underwent termination of pregnancy and three were born apparently normal. Among the 14 cases of VOUS, four underwent termination of pregnancy, four were born with CHD, and six were born apparently normal. Unfortunately, for now, our follow-up data end when the children were released from the hospital. Future studies will examine whether those children will develop cardiac symptoms. The reasons for the differences among the living children can be due to a number of reasons, including CNV penetrance and interactions with other genetic variants. Additional studies are necessary to better understand those CNVs.
It has been shown that the 22q11.2 deletion is related to cardiac anomalies. 32 Indeed, TBX1 is crucial to normal heart development. The prevalence of CNVs in 22q11.2 among fetuses with CHD is 1.6%-11.5%. 29, 32 Mercer-Rosa et al 33 reported that the 22q11.2 deletion was associated with the tetralogy of Fallot. In the present study, one case with the tetralogy of Fallot had the 22q11.2 deletion.
The other fetuses with the 22q11.2 deletion had ventricular septal defect.
In addition to the 22q11.2 deletion, CMA detected other deletions or duplications that were associated with CHD in the present Nevertheless, some study reported that the 15q11.2 deletion was associated with neurological diseases (including schizophrenia, idiopathic generalized epilepsies, and abnormal behavior), but the 15q11.2 deletion was also observed in healthy controls. 16, 36, 37 The knowledge about the penetrance of the 15q11.2 deletion on CHD is clearly incomplete. In the present study, the fetus with the 15q11.2 VOUS was born in December 2015 and displays no abnormality so far. Because potential benefits have to be weighed against risks, it is currently recommended that only pCNVs and likely pCNVs are to be disclosed to the parents 23 as VOUS can be associated with significant stress and anxiety. 10 Even in the presence of pCNVs, the benefits and risks have to be carefully weighed. Nevertheless, the present study provides additional data about the pathogenic potential of some VOUS because of their association with ultrasound-detected CHD.
Microarrays tests for SNPs not only provide data about CNVs but can also identify mosaics. In the present cohort study, CMA revealed an 11-M mosaic partial trisomy of chromosome 13q and a 24.4-M mosaic partial trisomy of chromosome 4q in one fetus.
The 4q region includes the HAND2 gene, which encodes transcription factors that play essential roles in cardiac morphogenesis. 38 Previous studies showed that overexpression of HAND2 affects heart development; indeed, HAND2-KO mice have right ventricle developmental defects and abnormal aortic arch arteries. 39 Tamura et al 40 showed that overexpression of Hand2 causes heart defects in fetuses with trisomy distal 4q. In the present study, the case with mosaic partial trisomy of chromosome 4q have the cardiac phenotypes of double outlet right ventricle, ventricular septal defect, persistent left superior vena cava, and pulmonary stenosis is consistent with precious report. 41 The present study is not without limitations. The sample size was relatively small. The follow-up mainly covered the pregnancy until termination or delivery, and the follow-up of the born children is short. CMA itself is a good and promising technique, but has some limitations such as its inability to detect balanced chromosomal rearrangements. 25 Genomic uncertainty is a challenge for genetic medicine. 12 Nevertheless, the present study underlines the usefulness of CMA in the prenatal genetic diagnosis of fetuses with CHDs and normal karyotype. In fetuses with CHD, the application of CMA could increase the detection rate of pCNVs causing CHDs. In this study, VOUS were identified as being potentially pathogenic, providing new data for adequate genetic counseling, but additional studies are needed to confirm these findings.
O RCI D
Jianfang Zhang
http://orcid.org/0000-0001-5074-4647
